

# silenceworks

BENITEC'S PROGRESS IN SILENCE

## Market Snapshot

### Market Data as at January 24, 2014

ASX Code:	BLT
Market Cap:	\$68.98 million
52 Week High/Low:	\$0.275 - \$0.86*
Shares on issue:	85.16 million
Industry sector:	Biotechnology


\* Converted to post consolidation pricing

### In this issue

- ▶ Benitec's 'first in man' Hepatitis C clinical trial to proceed
- ▶ TT-034 clinical trial in perspective—update from Benitec's CEO
- ▶ Lodge Partners revises Benitec's target price to \$1.00
- ▶ Benitec captivates mainstream and financial media



Learn about the company  
and the technology  
**WATCH THE VIDEOS**



### Benitec's 'first in man' Hepatitis C clinical trial to proceed

After filing an Investigational New Drug (IND) application with the US FDA in December 2013, Benitec received **advice** this month that we can proceed with the 'first in man' clinical trial of TT-034. Positive results will prove both TT-034's safety and efficacy in man, and demonstrate the potential of ddRNAi-based treatments for countless other human conditions. [More ▶](#)



### TT-034 clinical trial in perspective – update from Benitec's CEO

As Benitec gains the 'go-ahead' from the FDA and becomes a Clinical Stage Company, CEO and MD Dr Peter French outlines why this is one of the company's most significant milestones, how positive clinical data sparked Aynlam's initial rise in value (reaching US\$6billion this week) and the implications for Benitec's programs following recent developments in AAV vector technology. [Read the CEO Update ▶](#)



### Lodge Partners revises Benitec's target price to \$1.00

In its **research note** following the announcement that recruiting had begun for Benitec's Hepatitis C therapy TT034, Lodge Partners revised the company's target price upwards to \$1.00.

Lodge also added this comment: 'The listing of the trial site at Duke as open for recruitment occurred quicker than we believed it would, and indicates Benitec is well and truly on top of management of the trial'. [Read More ▶](#)



### Benitec captivates mainstream and financial media

In recent months interest in Benitec, its technology and potential, has spread widely: Benitec was named in **BRW's Top 5 Trends for 2013**, **The Australian** explored how biotechs like Benitec could help to fill the gap left by car manufacturers, **QANTAS** covered Benitec's origin and potential in 'The Australian Way', New York-based **OSix News** featured Benitec in its 'World Business Broadcast' and the **Bloomberg Brief** explored Benitec's advantages over other RNAi technologies, its IP strength and clinical trial approach. (Photo: BRW)